Qiagen (QGEN) Earns Coverage Optimism Score of 0.22
News coverage about Qiagen (NASDAQ:QGEN) has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Qiagen earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 43.9060287624523 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Zacks: Analysts Expect Qiagen NV (QGEN) Will Announce Quarterly Sales of $392.98 Million (americanbankingnews.com)
- BRIEF-Qiagen says it will Take Extraordinary After-Tax Charge On Net Income Of About $110-120 mln In Q4 2017 Due To US Tax Reform (QGEN) (uk.news.yahoo.com)
- Qiagen (QGEN) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
- Qiagen (QGEN) Take Impairment on Deferred Tax Assets, Informs … – StreetInsider.com (streetinsider.com)
- Analysts Expect Qiagen NV (QGEN) Will Announce Earnings of $0.41 Per Share (americanbankingnews.com)
A number of equities research analysts recently weighed in on QGEN shares. DZ Bank reaffirmed a “neutral” rating on shares of Qiagen in a report on Monday, August 28th. Cowen reaffirmed a “hold” rating and set a $33.00 price target on shares of Qiagen in a report on Thursday, September 28th. Zacks Investment Research raised Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a report on Tuesday, October 10th. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a report on Tuesday, November 7th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. Qiagen currently has a consensus rating of “Hold” and an average target price of $34.19.
Qiagen (NASDAQ:QGEN) last released its earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. The company had revenue of $364.00 million during the quarter, compared to analysts’ expectations of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the firm earned $0.29 EPS. equities research analysts forecast that Qiagen will post 1.25 earnings per share for the current year.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.